The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.
Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity
Open accessAbstract
The involvement of inflammation in cancer progression has been the subject of research for many years. Inflammatory milieu and immune response are associated with cancer progression and recurrence. In different types of tumors, growth and metastatic phenotype characterized by the epithelial mesenchymal transition (EMT) process, stemness, and angiogenesis, are increasingly associated with intrinsic or extrinsic inflammation. Among the inflammatory mediators, prostaglandin E2 (PGE2) supports epithelial tumor aggressiveness by several mechanisms, including growth promotion, escape from apoptosis, transactivation of tyrosine kinase growth factor receptors, and induction of angiogenesis. Moreover, PGE2 is an important player in the tumor microenvironment, where it suppresses antitumor immunity and regulates tumor immune evasion, leading to increased tumoral progression. In this review, we describe the current knowledge on the pro-tumoral activity of PGE2 focusing on its role in cancer progression and in the regulation of the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Donnini, S., Finetti, F., Solito, R., Terzuoli, E., Sacchetti, A., Morbidelli, L., Patrignani, P., & Ziche, M. (2007) · The FASEB Journal · doi:10.1096/fj.06-7581com · Cited by 96
Self-citationRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis
de Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D., & Plummer, M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70137-7 · Cited by 2,534
Cyclooxygenase in biology and disease
DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B. A., & Lipsky, P. E. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,506
Prostanoid Receptors: Structures, Properties, and Functions
Narumiya, S., Sugimoto, Y., & Ushikubi, F. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1193 · Cited by 2,412
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
Wang, D., & DuBois, R. N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2809 · Cited by 1,793
Cited by
Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy
Aboelella, N. S., Brandle, C., Kim, T., Ding, Z.-C., & Zhou, G. (2021) · Cancers · doi:10.3390/cancers13050986 · Cited by 286
Ferroptosis: principles and significance in health and disease
Chen, F., Kang, R., Tang, D., & Liu, J. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01564-3 · Cited by 285
Structure and post-translational modification of the prostaglandin transporter
Yu, P., Orlando, M. A., & Orlando, B. J. (2025) · Communications Biology · doi:10.1038/s42003-025-08510-0 · Cited by 3
Metadata
- Authors
- Finetti, F., Travelli, C., Ercoli, J., Colombo, G., Buoso, E., & Trabalzini, L.
- Venue
- Biology
- Publisher
- MDPI AG
- Published
- 2020-12-01
- Volume
- 9
- Issue
- 12
- Pages
- 434
- ISSN
- 2079-7737 (ISSN-L)
- OpenAlex
- W3109330936
- Cited by
- 302
- References
- 183
- FWCI
- 17.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity. https://app.cochat.ai/papers/10.3390/biology9120434
- The paper
- Finetti, F., Travelli, C., Ercoli, J., Colombo, G., Buoso, E., & Trabalzini, L. (2020). Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity. Biology. https://doi.org/10.3390/biology9120434
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.